Second Time’s The Charm: Amylyx’s ALS Drug Wins US FDA Panel Nod

In switching their votes from the first panel review in March, advisory committee members cited supportive additional analyses of a survival benefit, framing of the issues in the context of unmet need and regulatory flexibility, and the company’s statement that it would withdraw AMX0035 if the Phase III PHOENIX trial does not succeed.  

Yes and no
Amylyx flipped several votes from "no" to "yes" in its second visit to the advisory committee. • Source: Shutterstock

Amylyx Pharmaceuticals, Inc.’s amyotrophic lateral sclerosis drug AMX0035 (sodium phenylbutyrate/taurursodiol) appears on track for US Food and Drug Administration approval following a strongly favorable vote at its second advisory committee review.

In voting 7-2 for approval, four members of the Peripheral and Central Nervous System Drugs Advisory Committee switched their votes...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers